ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
32
views
0
references
Top references
cited by
15
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,998
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
Author(s):
CD Spinner
,
RL Gottlieb
,
GJ Criner
,
JR Arribas López
,
AM Cattelan
,
A. Soriano Viladomiu
,
JR Arribas
,
VA Soriano
,
C. Spinner
,
R. Gottlieb
,
G Criner
,
C.D. Spinner
,
R.L. Gottlieb
,
G.J. Criner
,
J.R. Arribas López
,
A.M. Cattelan
,
A.S. Viladomiu
,
O Ogbuagu
,
P. Malhotra
,
K.M. Mullane
,
A Castagna
,
L.Y.A. Chai
,
M Roestenberg
,
O.T.Y. Tsang
,
E BERNASCONI
,
P.L. Turnier
,
S.C. CHANG
,
S. SENGUPTA
,
R.H. Hyland
,
A.O. Osinusi
,
H CAO
,
C. BLAIR
,
H. Wang
,
H. Gaggar
,
D.M. Brainard
,
M.J. McPhail
,
S. BHAGANI
,
M.Y. Ahn
,
A.J. Sanyal
,
G Huhn
,
F.M. Marty
,
AS Viladomiu
Publication date:
2020
Journal:
JAMA.
Read this article at
ScienceOpen
Publisher
PubMed
Further versions
oa repository (via OAI-PMH doi match)
oa repository (via pmcid lookup)
Powered by
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
cGMP: Generators, Effectors and Therapeutic Implications Conference
Author and article information
Journal
DOI::
10.1001/jama.2020.16349
PubMed ID::
32821939
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,998
Remdesivir may not cure coronavirus but it’s on track to make billions for Gilead
Authors:
C. Rowland
Remdesivir for the treatment of Covid-19 ‐ preliminary report
Authors:
JH Beigel
,
KM Tomashek
,
LE Dodd
…
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS‐CoV‐2 induced pneumonia: A case report
Authors:
Zoran Sabljić
,
Nikolina Basic-Jukic
See all similar
Cited by
15
RBD-specific polyclonal F(ab´) 2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
Authors:
Gustavo Lopardo
,
Waldo H. Belloso
,
Esteban C. Nannini
…
Outcomes of Barotrauma in Critically Ill COVID-19 Patients With Severe Pneumonia
Authors:
Victor P. Gazivoda
,
Mudathir Ibrahim
,
Aaron Kangas-Dick
…
COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations
Authors:
Salin Nhean
,
Mario E. Varela
,
Y-Nha Nguyen
…
See all cited by